ROBUST CLINICAL TRIALS ARE NOT ENOUGH: OVERCOMING OPERATIONAL CHALLENGES FOR IMPLEMENTING REMSTART INTERVENTION PACKAGE (TRIP STUDY) INTO ROUTINE PRACTICE

Sokoine Kisuyo*, 1 Frank Erick, 2 Angela Loyea, 3 Shabar Jaffar, 4 Godfrey S Mfinanga, 1 National Institute for Medical Research-Muhimbili Centre, Dar es Salaam, Tanzania; 2 St. George’s University of London, UK; 3 Liverpool School of Tropical Medicine, Liverpool, UK

10.1136/bmjgh-2019-EDC.101

Background The REMSTART trial identified an effective package (cryptococcal antigen (CrAg) screening and enhanced anti-retroviral therapy (ART) adherence support) that reduced all-cause mortality in advanced HIV (CD4 ≤200 cells/mm³) by 28% compared to standard of care. The introduction of this package at clinic level has been necessary to impact routine care practices in Tanzania.

Methods The TRIP study was cluster-randomised. The intervention package was implemented in 16 routine care facilities (early arm) whilst 8 facilities continued with standard of care (deferred arm). At the end of 12 months follow-up, the intervention was implemented in the deferred facilities. The primary endpoint is all-cause mortality at 1 year.

Results Implementation of the REMSTART intervention into routine care services has highlighted the following challenges: 1) Baseline CD4 testing: half (4/8) of rural facilities had no CD4 machines and in a further 3/8 there was a lack of reagents needed for CD4 testing. Clinical staging has replaced inclusion criterion where CD4 testing is not available; 2) Heavy staff workload in routine care; regular discussion with policymakers and workshops enhanced the take-up of the package; 3) Timing of ART: The Ministry of Health has updated national guidelines to include the package and delay ART by 2 weeks in CrAg-positives.

Conclusion It has proven essential to engage with policymakers and programme managers from the outset, i.e. during the REMSTART trial itself and the following TRIP implementation study. The Ministry of Health has now changed the national HIV guidelines to include the REMSTART package and develop training modules for CrAg screening in all regional hospitals. The TRIP study has revealed key issues that must be addressed to allow scaling up the interventions.

ADVERSE DRUG REACTION TO TWO ARTEMISININ-BASED COMBINATION THERAPIES, ARTEMETHER-LUMEFANTRINE AND ARTEMISININ-PIPERAQUINE, IN CHILDREN WITH ACUTE UNCOMPlicated MALARIA IN IBADAN, NIGERIA

Oluwafunmibi Anjorin*, Catherine O Falade. Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria

10.1136/bmjgh-2019-EDC.102

Background Malaria remains a public health problem in sub-Saharan Africa, especially amongst children and pregnant women. Artemisinin-based combination therapy (ACT) is now the treatment of choice. Adverse drug reactions (ADR) have been observed to ACTs. This study aims to determine the incidence, pattern of presentation and factors associated with ADRs to artemether-lumefantrine (AL) and artemisinin-piperaquine (AP) among children with acute uncomplicated malaria in Ibadan, Nigeria.

Methods Children aged 2–10 years with acute uncomplicated malaria who met the inclusion criteria, were enrolled, randomised to receive one of the study drugs (AL or AP) and followed up for 28 days. Monitoring for ADR was based on history from the parent/guardian and/or child regarding occurrence of treatment emergent signs and symptoms and on abnormalities of laboratory investigations (full blood count and blood chemistry). Causality assessment for the ADR was by the Naranjo algorithm scale while the severity was assessed using the Hartwig’s severity scale.

Results A total of 114 children were enrolled; six defaulted and were not available for follow-up. There were 61 (56.5%) males. The mean age of enrollees was 65.1±30.0 months. Fever was the most prevalent presenting complaint occurring in 108 (100%) enrollees. Observed ADRs were cough, diarrhoea, loss of appetite, abdominal pain, rash, fever, irritability, insomnia and headache but the differences were not statistically significant between the two groups. The incidence of ADR to both ACTs was 12/1000 patients per day. Prevalence of ADR to AL was 14% and for AP 11%; this was not statistically significant. All ADRs were mild. No notable associated factor to ADR was detected in this study.

Conclusion Both AL and AP were found to be safe in the study population.

SCHISTOSOMA HAEMATOBUM INFECTION INCREASES THE NUMBER OF MALARIA EPISODES IN CHILDREN LIVING IN RURAL AREAS AROUND LAMBARÉNÉ, GABON

1 Jean Claude Dejon Agbò*, 1 Jean R Edoa, 1 Yabo J Honkebehdji, 2 Jeannot Fréjia Zinsou, 1 Bayodé R Adegbité, 1 Bertrand Lell, 2 Martin P Grobusch, 3 Benjamin Mordmüller, 1 Ayia Akin Adegriki. 1Centre de Recherches Médicales de Lambaréné (CERMEL), Libreville, Gabon; 2 Academic Medical Center, University of Amsterdam, the Netherlands; 3 University of Tübingen, Germany

10.1136/bmjgh-2019-EDC.103

Background In sub-Saharan Africa, Plasmodium spp. infection prevalence very often overlaps with helminth infections, particularly with schistosomiasis which is reported to be the second parasitic infection after malaria in terms of prevalence. Interaction between both infections has been reported earlier. Schistosomiasis is typically a chronic disease, whereas malaria occurs in episodes, particularly in children. In this study, we assessed the effect of Schistosoma haematobium infection on clinical malaria among children.

Methods A longitudinal study was conducted from June 2016 to February 2018. Volunteers without any known chronic condition were included. Thick blood smear (TBS) was performed monthly at participants’ homes. For any medical concern including malaria-like symptoms and visible haematuria, participants were invited to come to CERMEL for diagnosis and treatment. Light microscopy was performed to detect malaria parasites and Schistosoma eggs, using TBS and urine filtration technique, respectively. Over the study course, participants found to be infected were treated accordingly. Schistosomiasis status was determined at the end of the follow-up.

Results Among the 351 volunteers included in the study, schistosomiasis status was available for 260. Mean age was 12.3 year (SD 4.6) with a 0.96 women-to-men sex ratio. Of those, 112/260 (43.1%) [37.0%–49.3%] participants were
positive for *S. haematobium*, and a total of 132 (51%) children developed 230 malaria attacks. Those with schistosomiasis had a 1.5:1 [1.1–2.0] risk to develop malaria compared to their uninfected counterparts. The mean number of malaria episodes per child over the study course was higher among children with schistosomiasis compared to those without (2.03 vs 1.57, p-value=0.015).

**Conclusion** *S. haematobium* infection was associated with increased susceptibility to develop malaria (by increasing the risk to develop a malaria episode) and, consequently, a higher malaria incidence.

**PO 8456** POLYMORPHISM OF THE *PLASMODIUM FALCIPARUM* MSP-2 GENE ASSOCIATED WITH PLACENTAL MALARIA AT THE BORGOU-ALIBORI DEPARTMENTAL HOSPITAL

Dossou Alphadyé*, Saadou Issiou. Fondation pour le Recherche Scientifique, Cotonou, Benin

10.1136/bmjgh-2019-EDC.104

**Background** In sub-Saharan Africa, malaria during pregnancy is a major health problem because it poses significant risks for the pregnant woman and the foetus. The sequestration of *Plasmodium falciparum*-infected erythrocytes in the placenta has consequences for the mother and the foetus. This study aimed to evaluate the allelic polymorphism of the *Plasmodium falciparum* MSP-2 gene related to the consequences of placental malaria.

**Methods** It was a cross-sectional study conducted over two periods lasting six months in 2016 and 2017. The maternity center of the Hospital of Borgou-Alibori in Benin served as a framework for the study. From the 98 parturients included, placental blood samples were taken and then genotyped.

**Results** Using the MSP-2 gene as marker, the prevalence was 17, 34%. The MSP-2 gene was polymorphic with 9 distinct allelic types for both 3D7 and FC27 families (150 bp; 200 bp; 250 bp; 275 bp; 300 bp; 350 bp; 400 bp; 450 bp and 500 bp). The FC27 allelic family was predominant over the 3D7 family with 56, 25% and 43, 75% respectively. The 300 bp allelic type (50%) was predominant in the FC27 family while the 400 bp type was predominant in 3D7 family (35, 71%). 9 women had polyclonality (52,94%). The multiplicity of infection (MOI) was 1, 88. The number of strains ranged 1 to 4 in infected women. In univariate analysis there was no significant relationship between MSP-2 gene polymorphism and maternofoetal consequences. The absence of prenatal consultation (p=0.0270), non-taking of IPT/SP (p=0.0060), the occurrence of malaria in the third trimester (p=0.0364) and moderate maternal anaemia (p=0.0277) were associated with the polymorphism of MSP-2 gene. The MOI was significantly associated with parasite density of infected women.

**Conclusion** *Plasmodium falciparum* MSP-2 gene was polymorphic in infected women at Parakou. Several factors related to pregnancy monitoring were associated with this genetic diversity. It is therefore essential to ensure correct follow-up of pregnancies.

**PO 8460** PANDORA-ID NET (PAN-AFRICAN NETWORK FOR RAPID RESEARCH, RESPONSE, RELIEF AND PREPAREDNESS FOR INFECTIOUS DISEASES EPIDEMICS)

1Francine Ntoumi*, 2Francine Zumla, 3Giuseppe Ippolito, 4Francesco Vairo. 1Fondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of the Congo; 2University College of London, London, UK; 3National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy

10.1136/bmjgh-2019-EDC.105

**Background** New and re-emerging infectious disease outbreaks continue to cause much human suffering and loss of life worldwide. Since Africa has experienced repeated outbreaks of zoonotic infections, an important need exists to improve local and regional capacities to identify and respond to zoonotic outbreaks. PANDORA-ID-NET is an EDCTP-supported ‘ONE Human and Animal HEALTH’ multidisciplinary consortium of 24 partner institutions (15 African and 9 European) in 9 African and 4 European countries.

**Methods** Our overall aim is to strengthen regional and pan-African capacities and systems for enabling a rapid and effective response to infectious diseases with epidemic potential, arising from within Africa or imported from overseas. We aim to build laboratory and public health capabilities for rapid detection and surveillance of pathogens from human and animal sources. This will include obtaining accelerated evidence for optimal clinical management of patients, infection control measures, and public health response during outbreaks. Capacities will be built: a) for performing multisite clinical trials (evaluating rapid diagnostics, biomarkers, a range of treatments, vaccines and operational research studies) and, b) for timely collection, analysis and communication of information.

**Conclusion** Our activities will be aligned to EDCTP regional Networks of Excellence, Africa CDC and other relevant global and regional initiatives, thus maximizing complementarity and achieving a multiplier effect, facilitating rapid policy implementation of outputs.

**PO 8467** IMPACT OF COMMUNITY CASE MANAGEMENT OF MALARIA (CCMM) AMONG CHILDREN UNDER FIVE YEARS OLD: AN EVALUATIVE STUDY IN KABONGA

1Ciza Bonne*, 2Kagozi Husseni, 3Ciza Josephine Muhigirwa. 1Health Healing Network Burundi, Bujumbura, Burundi; 2Solidarity of nurses for promotion of maternal and children’s health, Burundi; 3Palliative care association of Burundi, Bujumbura, Burundi

10.1136/bmjgh-2019-EDC.106

**Background** In Burundi, malaria is considered a major public health concern and the leading cause of death. Malaria is responsible for up to 25% of all outpatient visits and up to 48% of all deaths in health facilities among children under five years old. Despite efforts made, timely access to health care is still limited, mainly due to geographic inaccessibility and lack of awareness about malaria complications. To increase timely access to malaria treatment, Burundi’s Ministry of Health implemented Community Case Management of Malaria (CCMM) since 2015 in Kabonga. We sought to assess the impact of CCMM in improving malaria outcomes following two years of its initiation.